Fundraising FoxDecheng Capital — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)inTrevor Martin(Founder)inJanice Chen(Founder)inLucas Harrington(Founder)inAshley Tehranchi(Founder)in
BoardUrshit Parikh(Director)
Co-investors8VCBerkeley FrontierCalifornia Innovation FundForesite CapitalMayfield FundMission Bay Capital+12 more
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
BiotechSan Diego, US
David S. Mullarkey(Executive Officer, Director)Arnold Oliphant(Executive Officer)inKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)
Co-investorsARCH Venture PartnersATEL VenturesDCVC (Data Collective)Lam CapitalPivotal Life SciencesALTITUDE LIFE SCIENCE VENTURES+3 more
Polares Medical is a medical device company developing a device for treating mitral valve regurgitation.
HealthtechMedical DevicesPalo Alto, US
Alex Khairkhahan(Founder)in
Co-investorsLongitude CapitalEarlybird Venture CapitalEndeavour VisionIDO Investments
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)
Co-investorsLAVLilly Asia VenturesLilly VenturesVivo Capital
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program.
BiotechHealthtechFoster City, US
Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)inSenthil Sundaram(Director, Executive Officer)inWeidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)inDavid Fellows(Director)
Co-investorsLAVLilly Asia VenturesVivo Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.